With 0.55 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.18 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $4.589 whereas the lowest price it dropped to was $4.13. The 52-week range on CLLS shows that it touched its highest point at $3.83 and its lowest point at $1.10 during that stretch. It currently has a 1-year price target of $5.50. Beta for the stock currently stands at 3.07.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CLLS was up-trending over the past week, with a rise of 30.70%, but this was up by 50.88% over a month. Three-month performance surged to 160.61% while six-month performance rose 253.04%. The stock gained 138.89% in the past year, while it has gained 127.03% so far this year. A look at the trailing 12-month EPS for CLLS yields -0.57 with Next year EPS estimates of -0.97. For the next quarter, that number is -0.23. This implies an EPS growth rate of -113.80% for this year and -10.23% for next year.
Float and Shares Shorts:
At present, 100.33 million CLLS shares are outstanding with a float of 61.80 million shares on hand for trading. On 2025-09-15, short shares totaled 0.26 million, which was 26.0 higher than short shares on 1755216000. In addition to Dr. Andre Choulika Ph.D. as the firm’s Co-Founder, CEO & Director, Dr. David J. Sourdive Ph.D. serves as its Co-Founder, Deputy CEO, Executive VP of CMC & Manufacturing and Director.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-06-30, CLLS reported revenue of $16725000.0 and operating income of -$9587000.0. The EBITDA in the recently reported quarter was -$2375000.0 and diluted EPS was $nan.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CLLS since 1 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With CLLS analysts setting a high price target of 10.0 and a low target of 3.0, the average target price over the next 12 months is 5.6. Based on these targets, CLLS could surge 132.56% to reach the target high and fall by -30.23% to reach the target low. Reaching the average price target will result in a growth of 30.23% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.40872 being high and -$1.02528 being low. For CLLS, this leads to a yearly average estimate of -$0.63292. The surprise factor in the prior quarter was $0. Based on analyst estimates, the high estimate for the next quarter is -$0.11 and the low estimate is -$0.11. The average estimate for the next quarter is thus -$0.11.
